Diagnostics and software startups were active on the New England-area deals front this week. We saw news of acquisitions, financings, and stock purchases, and also covered some more in-depth strategy at a big area tech name.
—Pathogenetix, a Woburn, MA-based diagnostics startup formerly named U.S. Genomics, brought in $1.3 million in equity-based funding, and $900,000 of a targeted $1.2 million debt offering, according to two SEC filings. While under the U.S. Genomics name, the firm raised $4.5 million in private equity funding from Becton, Dickinson, & Co. to develop infectious disease diagnostics technology.
—Cambridge, MA-based Daktari Diagnostics wrapped up a $1.8 million equity investment, a regulatory filing revealed. The deal brings the funding pot to more than $5.5 million for Daktari, a biotech that is pursuing a system for testing HIV patients’ blood in locations lacking sophisticated lab technology.
—GTC Biotherapeutics, a Framingham, MA-based company that was the first to get FDA approval for a drug produced by genetically modified animals, was bought by LFB Biotechnologies for 30 cents per share, a total of $18.3 million. The deal will give France-based LFB Biotechnologies a 90 percent stake in GTC. The firm will also cash out all of GTC’s minority shareholders for $2.7 million total.
—Greg took a look at the acquisition and innovation strategies at Hopkinton, MA-based data storage giant EMC (NYSE: [[ticker:EMC]]). The firm, which last year bought Santa Clara, CA-based Data Domain for $2 billion and is rumored to be eyeing Seattle-based Isilon Systems (NASDAQ: [[ticker:ISLN]]), plans to
